Clinical Lymphoma Myeloma & Leukemia

Article	Citations
Survival Benefit and Efficiency of Low Dose Decitabine With CEG Regimen Compared to Decitabine Alone in the Elderly MDS – A Multicenter, Retrospective Study	46
Treatment-Induced Aggravation of Vasculitis in Hairy-Cell Leukemia	45
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study	42
Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia	35
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma	34
Characteristics and Outcomes of Secondary Acute Myeloid Leukemia and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Multicenter Study From the Thai Acute Leukemia Study Group	32
IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era	32
Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study	30
Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies	29
Clinical Analysis of Pediatric T-Cell Acute Lymphoblastic Leukemia Using the MRD-Oriented Strategy System	28
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no	28
Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma	27
CD19 CAR-T With Axicabtagene Ciloleucel in R/R Large B-Cell Lymphoma With/Without Prior Autologous Stem Cell Transplant	27
Table of Contents	25
Table of Contents	25
Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma	24
P-175 Improving Anti-BCMA CAR-T functionality with novel immunomodulatory agent Iberdomide (CC220) in Multiple Myeloma	23
Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China	22
SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia	22
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome	20
Table of Contents	20
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration	19
Updates in the Management of Primary Mediastinal B Cell Lymphoma	19
Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group	19
Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience	19

Long-Term Efficacy of High-Dose Imatinib in Hispanic Patients Without Access to Second-Generation Tyrosine Kinase Inhibitors Treated in LATAM Centers	19
Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience	18
Descriptive Analysis and Factors Influencing Survival in Patients With Primary Cutaneous Gamma-Delta T Cell Lymphoma. A Retrospective National Cancer Database Study.	18
MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis	17
Editorial Board	17
Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell–Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab T	17
Concurrent TP53 Mutation and Deletion in Refractory Low-grade Follicular Lymphoma	16
Editorial Board	15
Editorial Board	15
CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study	15
Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival	15
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospec	15
Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML	14
MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (M	14
Plasmablastic Lymphoma: Past, Present, and Future	14
Outcomes After Salvage Autologous Hematopoietic Cell Transplant for Patients With Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience	14
P-113 An Artificial Intelligence-Based 3D-Segmentation Assessment of Sarcopenia Utilizing Whole-Body Computed Tomography in Patients With Multiple Myeloma	14
OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple mye	14
P-208 Clonal Evolution of Multiple Myeloma Following the Mutagenic Impact of Radiotherapy	13
OA-13 Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-	13
P-134 The Efficacy of Acupuncture in Alleviating Bortezomib-Associated Peripheral Neuropathy in Patients with Multiple Myeloma: A Comparative Study	13
P-185 Single Tube Twelve Color Flow Cytometric Myeloma MRD Assay- A Single-Center Experience From Eastern India	13
P-139 Perceptions of Brazilian Hematologists in the Care of Patients with Multiple Myeloma in the Unified Health System: Brazil of Contrasts	13
P-104 Empowering Multiple Myeloma Patients: Impact of MMRF Education Programs and Results Of Patient Outcomes	13
P-049 Teclistamab in Real Life: Can We Shorten the Ramp-Up?	13
P-156 Cryotherapy Prevents Hair Loss in Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation	13
P-154 Multidisciplinary, Patient-Centric Bone Disease Management in Multiple Myeloma – a Single-Centre Experience	13
P-121 Prevalence of Multiple Myeloma in Ecuadorian Hemodialysis Units. A SEN Study	13
P-108 Exploring the Role of the Combination of FDG-PET Plus Whole Body MRI for Staging Patients in High Risk Smoldering Myeloma: A Prospective Trial	13
P-160 Investigation of the Radiological Techniques To Detect Osteolytic Lesions, Fractures, and Osteoporosis in Multiple Myeloma Patients	13
P-127 The Role of Spinal Bracing in the Management of Multiple Myeloma Spinal and Sternum Disease	13
P-112 Fall Risk Assessment and Fall Prevention in Patients With Multiple Myeloma: First Results of the MYFALL-Trial	12
P-195 Heterogeneity of Osteoclasts in Multiple Myeloma Revealed by Single Nucleus RNA Sequencing	12
P-189 Microbiome Analysis in Bone Marrow Reveals Distinct Bacterial Profiles Across Multiple Myeloma Stages	12
P-072 Health Care Resource Utilization and Economic Burden of Cytokine Release Syndrome Management in Patients With Multiple Myeloma Receiving CAR-T Cell and Bispecific Antibody Therapies	12
P-186 Identifying a New Risk-Stratification Strategy by Including Single-Cell Biomarkers in Multiple Myeloma	12
P-114 Multiple Myeloma Associated With Other Primary Malignant Neoplasms: Epidemiological Characteristics Over 20 Years of Hospital Cancer Registry	12
P-155 Evaluation of Pseudo-CT MRI Sequences (Zero-Echo-Time (ZTE) and Back Bone (BB) Gradient-Echo) for the Detection of Lytic Bone Lesions in MM: Comparison with PET/CT	12
P-100 Outcomes of R/R MM Patients with Renal Function Impairment Treated with Eque-cel in the Pivotal Phase 2 FUMANBA-1 Study	12
P-126 Characteristics and Outcomes of Patients With Multiple Myeloma Aged ≤ 40 Years – Experience From a Tertiary Care Cancer Centre in India	12
Table of Contents	11
P-031 Phase I Study to Evaluate Cellular Immunotherapy Using CS-1 Targeting Autologous CAR T Cells in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)	11
P-202 Risk Factors Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with Front-Line VRD Regimen	11
P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma	11
P-005 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma	11
P-138 Real World Single Centre Experience On The Use of Radiotherapy In The Treatment of Patients with Multiple Myeloma	11
P-198 Immunomodulatory Effects of Daratumumab on the Bone Marrow Microenvironment in Multiple Myeloma: Insights from Single-Cell Analyses	11
P-062 QUINTESSENTIAL: A Multicenter Phase 2 Study Evaluating the Efficacy and Safety of BMS-986393 in Patients With Quadruple-Class Exposed Relapsed or Refractory Multiple Myeloma	11
P-150 Rapid Whole-Body PET/MRI With Fat-Suppressed T2-Weighted Imaging Is Superior to Whole-Body PET/MRI With Diffusion-Weighted Imaging (DWI) in Plasma Cell Disorders	11
OA-03 Talquetamab (tal) + Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-Up	11

P-232 Comprehensive Genomic Sequencing Predicts Sub-Optimal Response to Bispecific Antibodies (BsAb) and Chimeric Antigen Receptor T Cells (CAR-T) in Multiple Myeloma (MM)	10
P-219 Longitudinal Analysis of t(11; 14) and t(4; 14) Genomes Reveals Distinct Evolutionary Trajectories in Multiple Myeloma	10
P-334 Ixazomib-Based Maintenance Therapy in Multiple Myeloma Patients Eligible and Ineligible for Transplantation: A Real-World Study (INFINITE Study)	10
OA-01 Talquetamab (tal) + Daratumumab (dara) + Pomalidomide (pom) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM-2 Study	10
P-288 Impact of the Addition of Daratumumab to the Frontline Treatment of Patients With Al Amyloidosis	10
OA-24 A Novel Mouse Model Engineered With Human Immune System Is a Translationally-Important Model for Studies Related to Immune-Microenvironment and Immunotherapies in Multiple Myeloma	10
P-045 Idecabtagene Vicleucel (ide-cel) in Patients (pts) With Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Front-Line (1L) Autologous Stem Cell Transplantation (ASCT): KarMMA-2 Cohor	10
OA-62 Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myelo	10
P-289 Outcomes of Incorporating IV Daratumumab for the Treatment of Al Amyloidosis in Real World Patients From a Multicenter Registry in Latin America	10
P-220 Profiling of Immune Checkpoints in the Myeloma Microenvironment	10
P-263 Disrupting the Lysosome and Autophagy via PIKfyve Inhibition is a Potential Novel Therapeutic Approach in Multiple Myeloma	10
P-014 Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 Trial	10
P-342 Impact of Achieving <VGPR With Dara-RVD Induction Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients	10
OA-16 Long-Term Evaluation of Minimal Residual Disease Dynamics in Multiple Myeloma Patients Achieving Complete Response After First Line Treatment	10
P-297 Monoclonal Gammopathy of Renal Significance: How Should We Evaluate Response? Experience in a Hospital Complex	10
P-068 Developing Novel DKK1-A2 CAR-T Cell Therapy for Myeloma and Other Hematologic Malignancies	10
P-020 Treatment Positioning Model to Evaluate the Survival Benefit of Ciltacabtagene Autoleucel in Second-Line Compared With Later-Line Treatment of Lenalidomide-Refractory Multiple Myeloma	10
P-330 Stem Cell Mobilization Strategy With Pegilgrastim for Stem Cell Transplantation for Multiple Myeloma: A Direct Cost Comparison	10
P-369 Optimizing the Alcyone Trial: Efficacy of Daratumumab And Bortezomib Maintenance in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma Patients Post Dara-Vmp Induction, 1 Year Analysis	10
P-278 Brazilian Relapsed Refractory Multiple Myeloma Patients Treated with Teclistamab Outside of Clinical Trials as an Expanded Access Program	10
OA-34 HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma	10
P-372 Treatment of Multiple Myeloma in the Public Health System in Brazil: Results of 9 Years of Treatment	10
OA-27 Para-Medullary (PMD) and Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants and Genomic Complexity Compared to Marrow-Based Myelom	10
P-086 Clinical Outcomes of Teclistamab among MajesTEC-1 Eligible and Ineligible Population in the Real-World Setting for the Treatment of Relapsed/Refractory Multiple Myeloma	10
P-426 Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ	10
P-316 A Retrospective Analysis of the Efficacy and Safety of a Single-Center Daltuzumab-Based Treatment for Light Chain Amyloidosis	9
P-391 Isatuximab-Carfilzomib-Dexametasone (Ikd) in Patients with Multiple Myeloma with Relapsed/Refractory Disease: Real-Life Results in Seven Spanish Centers	9
P-271 YM155 Exerts Anti-Myeloma Effects via Myc/BBC3 Signaling Pathway in Vitro	9
P-364 A Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older than 65 Years	9
AUTHOR INDEX	9
P-407 Real-World Outcomes in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) With Prior Proteasome Inhibitor and Lenalidomide Exposure in Sweden	9
P-311 Systemic Treatment Outcomes in Relapsed or Refractory POEMS Syndrome – Analysis from the UCLH POEMS Centre Registry Spanning 25 Years	9
P-319 First-Line Treatment Landscape in Multiple Myeloma: Analysis of Stem Cell Transplantation and Drug Utilization in Brazil and Argentina from the TOTEMM-A and TOTEMM-B Real-World Studies	9
P-253 Proteogenomic Analysis of Hyperdiploid Multiple Myeloma	9
NSO-03 Validation of the Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM) with Concurrent Symptom and Quality of Life Measurement (EORTC QLQ-C30 and MY20)	9
NSP-03 Real-world Experience in Treating MM and Amyloidosis Patients with Teclistamab and Talquetamab in the Private Setting in the UK	9
P-302 Correlative Analysis Between the 20-2-20 Score and 3D Telomere Profiling in Stratifying Smouldering Myeloma Patients	9
P-314 Daratumumab for Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin G Deposits and Severe Chronic Kidney Disease	9
P-309 Diagnostic Challenges in Systemic Amyloidosis: Exploring the Impact of Mass Spectrometry in a Middle-Income Country Cohort	9
P-366 Pre-Transplant Factors Predict Long-Term Outcomes in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation in a Resource-Limited Setting	9
P-383 Novel Selinexor Triplet and Quadruplet Regimens (SNd, SPEd, SBd, SDPd): Results from the Phase 1b/2 STOMP Multiple Myeloma Trial	9
P-419 Successful Pregnancy Outcome and CR 4 Transplant in a Patient of Multiple Myeloma	9
POSTER: IBCL-318 Epidemiological, Clinical, Histopathologic and Therapeutic Characteristics of Marginal Zone Lymphoma: Experience of the Hematology Department of Casablanca in Morocco	8
P-401 Real-World Experience With Talquetamab Clinical Management in Relapsed Refractory Multiple Myeloma (RRMM): A Qualitative Study of US Healthcare Providers	8
P-409 Real-Life Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Carfilzomiband/or Pomalidomide-Based Regimens in the LocoMMotion and MoMMent Studies	8
P-307 Waldenstrom's Macroglobulinemia: Clinical Presentation and Treatment Outcome From a Tertiary Care Centre From India	8
POSTER: IBCL-188 Hairy Cell Leukemia: A Single Center Analysis from India	8
POSTER: MCL-153 Ibrutinib Therapy in Relapsed/Refractory Primary Central Nervous System Lymphomas	8
POSTER: TCL-054 A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-Cell Lymphoma: Impact of Autologous Stem Cell Transplant (ASCT)	8
POSTER: ABCL-039 Metformin in Combination With the Standard Therapy in Patients With Diffuse Large B-Cell Lymphoma: A Randomized Phase II Clinical Trial	8
P-318 A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma	8
P-412 Real World Outcomes with Elotuzumab-Based Therapies for Patients with Relapsed Refractory Multiple Myeloma (RRMM): A Mayo Clinic Experience	8
NSP-11 Predictive Factor for Higher Level of Preferences for Cure and Survival in Myeloma	8
P-315 Safety and Efficacy of Elranatamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series	8
Editorial Board	8
POSTER: ABCL-222 Diffuse Large Cell Lymphoma of the Uterus Presented With Vaginal Bleeding: A Case Report	8
P-090 Clinical characteristics and risk of progression in patients with monoclonal gammopathy of uncertain significance: long-term experience in a single tertiary hospital	8
P-418 Subcutaneous Administration of Isatuximab by an On-Body Delivery System (OBDS) in Multiple Myeloma Patients: Results of a Nurse Survey	8
P-388 Clinical Efficacy of Isatuximab Plus Carfilzomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: An Italian Real-Life Multi-Center Retrospective Experience	8
P-244 Effects of Daratumumab(dara), Cyclophosphamide (C), Thalidomide (T) and Dexamethasone (D) Combination on Lymphocyte Populations of Transplant Eligible Newly Diagnose Multiple Myeloma Patients	8
Editorial Board	8
Table of Contents	8
P-110 Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: final overall survival analysis from the TOURMALINE-MM4 study	8
P-051 Safety and efficacy of chimeric antigen receptor T cell therapy in patients with relapse or refractory multiple myeloma and hepatitis B virus-infection	7
P-026 Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma	7
POSTER: IBCL-098 TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)	7
POSTER: ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma	7
P-092 High serum free light chains levels in African ancestry population screened for monoclonal gammopathy: implication for definition of FLC reference range accounting for renal function and race	7
P-156 Outcomes of a bortezomib-based induction regimen (sequential or upfront triple association with lenalidomide) in transplant-eligible patients withh newly diagnosed multiple myeloma	7
P-128 Daratumumab – VTD vs VTD: peri-transplant evaluation	7
POSTER: TCL-330 RHOA G17V Potentiates CD28-Induced NFAT Transcriptional Activity by Modulating p300 Activity: A Step Further in the Understanding of Follicular Helper T-Cell Lymphoma	7
POSTER: MCL-639 Clinical Features and Primary Treatment Outcomes for Mantle Cell Lymphoma: Peruvian National Cancer Institute	7
POSTER: ABCL-069 Prognostic Value of Time of Relapse in Patients With Diffuse Large B-Cell Lymphoma	7
OAB-055: Updated results of a phase 1, first-in-human study of ABBV-383, a BCMA × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma	7
P-019: Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-ce	7
POSTER: HL-603 Hodgkin Lymphoma in Tripoli University Hospital Libya	7
P-065 Whole body low dose CT (WBLDCT), as initial imaging modality for newly diagnosed multiple myeloma patients: experience from a teritary care center in North India	7
POSTER: MM-074 How can Different Therapeutic Strategies and Financial Resources Impact Outcomes After Autologous Stem Cell Transplantation in Myeloma? Study in France and Algeria	7
POSTER: IBCL-218 Parotid Gland Extramedullary Hairy Cell Leukemia: A Case Report With Review of Literature	7
P-139 Impact of melphalan staggered dosing prior to autologous hematopoietic cell transplantation for multiple myeloma patients	7

P-068 Implementation of next generation sequencing as best tool for routine evaluation of minimal residual disease in the daily practice of multiple myeloma patients	7
P-056 Role the combination of FDG pet plus whole body MRI for staging patients in high risk smoldering myeloma: a prospective trial	7
P-070 Failure to clear circulating tumor cells after one week of daratumumab, bortezomib and dexamethasone is associated with a reduced progression-free survival for myeloma patients	7
OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multipl	7
POSTER: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the P	7
P-054 Optimizing the Vk*MYC multiple myeloma model to investigate osteolytic bone lesions	7
POSTER: MM-348 Fluorescence in situ Hybridization (FISH) t(11;14) Testing Practices Over Time in Patients With Newly Diagnosed Multiple Myeloma (MM) in the USA in the Flatiron Health Database	7
POSTER: TCL-196 Hepatosplenic T-Cell Lymphoma in Adolescents and Young Adults: A Case Report	7
POSTER: TCL-154 STAT3 Mutations are Associated With Differential Treatment Responses to Methotrexate and Cyclophosphamide in T-Large Granular Lymphocyte Leukemia	7
P-100 Prevalence of monoclonal gammopathies in adult Uruguayan population	7
POSTER: IBCL-297 Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL)	7
P-009 Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myeloma	6
POSTER: MPN-091 Indirect Treatment Comparison of Momelotinib vs Fedratinib Safety in Patients With Myelofibrosis	6
POSTER: MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia	6
POSTER: MDS-601 Human Factors Validation Study for a Wearable, Single-Use Injector	6
POSTER: MPN-498 Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation an	6
P-024 Early outcomes and therapy modification strategies in multiple myeloma patients treated with teclistamab, CD3XBCMA BITE: a single center experience	6
OA-38 Physical activity interventions to improve functional performance in patients with multiple myeloma	6
P-021 Durable response to CAR T cell treatment is associated with the downstream triggering of native T cell immunity: a lesson learned from B cell lymphoma patients	6
OA-50 Pharmacodynamic effects of tiragolumab, as monotherapy and in combos with daratumumab and atezolizumab in patients with R/R MM: biomarker results from a phase 1a/1b trial	6
AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemother	6
Poster: AML-320: A Prospective Evaluation of WT1 Gene Expression in Primary Acute Myeloid Leukemia: Bench to Bedside	6
POSTER: MPN-227 Insight into Hypereosinophilia from the Hematology Clinic; A Single-Center Experience	6
OAB-040: BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3	6
POSTER: ABCL-142 Efficacy and Safety of Single-Agent Blinatumomab as Salvage Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia (B-ALL): Real-Life Experience	6
CT-342 Prolonged Hematologic Toxicity After B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Treatment: From Clinical Data to Ex-Vivo Studies at a Single Center	6
P-001: RNA-sequencing reveals transcriptomic similarity of AL amyloidosis and MGUS aberrant plasma cells along with several potential ALA target candidate genes	6
P-010 Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel)	6
P-003: A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)	6
CLL-240 Frequency of IKZF3 L162R Mutation in B-Cell Lymphoproliferative Disorders	6
POSTER: HL-281 Treatment of Relapsed Hodgkin Lymphoma With Pembrolizumab as Monotherapy	6
POSTER: MPN-193 Incidence of Blast Phase in Myelofibrosis According to Anemia Severity	6
AML-108 SELECT-AML-1 Trial in Progress: A Phase 2 Study of Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-Positive AML who are Ine	6
P-213: A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myeloma	6
P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple	6
P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical s	6
POSTER: MPN-092 Indirect Treatment Comparisons of Momelotinib vs Pacritinib Safety and Anemia Outcomes in Patients With Myelofibrosis	6
P-033 Real world evaluation of teclistamab in patients with RRMM: results from the IMF immunotherapy database project	6
POSTER: HL-561 Treating Refractory Immune Thrombocytopenia (ITP) in the Context of Concomitant Papillary Thyroid Carcinoma (PTC) and Hodgkin Lymphoma (HL): A Rare Case Report	6
AML-197 Incidence of Infectious Lung Disease in Neutropenic Patients	6
POSTER: HL-214 Breast Pleomorphic Liposarcoma in a Case With a History of Hodgkin Lymphoma	6
P-003 Clinical outcomes among multiple myeloma and lymphoma patients taking beta-blockers undergoing CAR-T therapy	6
P-020: PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer	6
OAB-019: Proteogenomic screens reveal that RAS commandeers the amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma	6
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia	6
OA-40 Frailty and initial treatment intensity in patients newly diagnosed with multiple myeloma	6
Poster: AML-282: Prognostic Values of D816V KIT Mutation and Peri-Transplant CBFB-MYH11 MRD Monitoring on Acute Myeloid Leukemia with CBFB-MYH11	6
CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study	6
POSTER: ALL-020 Localized and Generalized Lymphadenopathy Referred to 3 Tertiary Pediatric Centers Over 6 Years: The Alarming Signs	5
P-060: Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single cell transcriptomics	5
P-053: BoBafit: a Copy Number-clustering tool to refit and recalibrate the diploid region of Multiple Myeloma genomic profiles	5
ABCL-411 Management of DLBCL (Diffuse Large B-Cell Lymphoma): A Monocentric Experience	5
Chronic Eosinophilic Leukemia: Diagnosis and Therapy	5
P-056: HUWE1 orchestrates DNA Repair in response to Replicative Stress in Multiple Myeloma	5
POSTER: AML-211 Acute Leukemia (AL) and Pregnancy: Single-Institution Experience	5
Poster: CT-227 Dual CAR-Engineered NK92 Cells: An Off-the-Shelf Cell Therapy for Cancer	5
Poster: ABCL-102 A SEER-Medicare Analysis of the Cost of Disease Progression After Frontline R-CHOP in Diffuse Large B-Cell Lymphoma	5
Poster: CT-026 Prevalence and Impact of Donor Specific Anti-HLA Antibodies in the Setting of Myeloablative Haploidentical Transplant for Malignant Hematological Diseases: Single-Center Experience	5
Editorial Board	5
MM-368 Iraqi Metadata Analysis of Diagnosis, Risk Stratification, and Management of Multiple Myeloma	5
ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma	5
Poster: AML-295: Clinical Characteristics and Outcome of Acute Leukemia in Lebanese Patients: A Retrospective Observational Analysis	5
POSTER: ALL-023 Outcome of Adult Acute Lymphoblastic Leukemia: A Single-Center Experience	5
Poster: AML-108: Exogenous Mitochondrial Transfer and Endogenous Mitochondrial Fission Facilitate Resistance to OxPhos Inhibition in AML	5
Treatment of Lower Risk Myelodysplastic Syndromes MDS	5
POSTER: AML-240 Understanding Physicians’ Approach to Diagnosis and Treatment of Acute Myeloid Leukemia Disease in Türkiye: Turkish Hematology Networking Group Survey	5
Prognostication and Treatment of Burkitt Lymphoma in the Modern Era	5
POSTER: ALL-555 Acute Lymphocytic Leukemia in Pregnancy, Case Report and Review of the Literature	5
CT-150 COVID-19 Vaccination–Associated Acquired Thrombotic Thrombocytopenic Purpura (TTP)	5
Prophylaxis and Management of Secondary CNS Lymphoma	5
POSTER: CLL-237 Efficacy of Cladribine Combine With Rituximab versus Cladribine Alone in the Treatment of Hairy Cell Leukemia: A Retrospective Single-Center Study	5
Poster: MPN-141 Retrospective Comparison of Patient Outcomes on Pacritinib Versus Ruxolitinib in Patients With Myelofibrosis and Thrombocytopenia	5
CT-107 Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel), as Second-Line (2L) Treatment of Large	5
Poster: MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood	5
P-161: Ultra-high-risk prognostic significance of double and triple hit myeloma	5
Poster: HL-526 Improved Survival of Elderly Patients With Classical Hodgkin Lymphoma (cHL) in the Modern Era - A SEER-Registry Analysis	5
CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)	5
Poster: MPN-215 Outcomes of Myelofibrosis Patients Post Allogeneic-HSCT at the University of Southern California, a Retrospective Study	5
Poster: HL-370 Fragmentome Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma	5
P-086: Quantitative seroproteomics analysis of Multiple Myeloma patients treated with Tagraxofusp, a novel CD123-directed targeted therapy, identifies novel cytokine-mediated mechanism of action	5
POSTER: AML-260 A Metabolically Optimized, Non-Cytotoxic Low-Dose Weekly Decitabine/Venetoclax Regimen in MDS and AML	5
P-065: CyTOF and single cell RNA sequencing reveal altered T cell phenotypes in Multiple Myeloma patients: implications for immunotherapy	5
Poster: MPN-354 Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years	5
ABCL-276 Neurolymphomatosis: A Rare Presentation Mimicking a Schwannoma	5
Poster: HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1	5
P-040: CD138-independent strategy to predict relapse in Multiple Myeloma patients	5
Poster: CT-347 Acute Graft-Versus-Host Disease: Risk Scoring and Response to Treatment, Experience From Two Centers	5
POSTER: AML-080 Modeling Flotetuzumab-Associated Cytokine Release Syndrome (CRS) in AML Using In Vitro and In Vivo Preclinical Models	5
Poster: CT-514 Acute Cardiac Tamponade Following Adult Allogeneic Hematopoietic Transplantation	5
ABCL-181 Germinal Center Double Hit Diffuse Large B-Cell Lymphoma Refractory to Chemoimmunotherapy: A Case Report	5
Poster: ALL-258: Loss of Heterozygosity in STR Loci Found in Tumor DNA of De NOVO-Diagnosed ALL Patients as a Factor Predicting Poor Outcomes for B-ALL but Not T-ALL Patients	5
ABCL-269 Secondary Central Nervous System (CNS) Involvement in Diffuse Large B Cell Lymphoma (DLBCL): Ten-Year Outcomes From Mexico's National Cancer Institute	5
AML-156 Early Deaths in Patients With Newly Diagnosed Acute Promyelocytic Leukemia: A Single-Center Retrospective Study From a General Hospital	5
POSTER: AML-047 Risk Factors Beyond Chemotherapy Exposure for Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML) Development in Lymphoma Survivors: A 15-year SEER-Medica	5
AML-327 Novel Anti–B7-H3 Blocking Antibody Enhances NK Cell–Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice	5